Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2014

01-01-2014 | Review

A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications

Author: G. P. Fadini

Published in: Diabetologia | Issue 1/2014

Login to get access

Abstract

Traditionally, the development of diabetic complications has been attributed to the biochemical pathways driving hyperglycaemic cell damage, while reparatory mechanisms have been long overlooked. A more comprehensive view of the balance between damage and repair suggests that an impaired regenerative capacity of bone marrow (BM)-derived cells strongly contributes to defective re-endothelisation and neoangiogenesis in diabetes. Although recent technological advances have redefined the biology and function of endothelial progenitor cells (EPCs), interest in BM-derived vasculotropic cells in the setting of diabetes and its complications remains high. Several circulating cell types of haematopoietic and non-haematopoietic origin are affected by diabetes and are potentially involved in the pathobiology of chronic complications. In addition to classical EPCs, these include circulating (pro-)angiogenic cells, polarised monocytes/macrophages (M1 and M2), myeloid calcifying cells and smooth muscle progenitor cells, having disparate roles in vascular biology. In parallel with the study of elusive progenitor cell phenotypes, it has been recognised that diabetes induces a profound remodelling of the BM stem cell niche. The alteration of circulating (progenitor) cells in the BM is now believed to be the link among distant end-organ complications. The field is rapidly evolving and interest is shifting from specific cell populations to the complex network of interactions that orchestrate trafficking of circulating vasculotropic cells.
Literature
1.
Avogaro A, de Kreutzenberg SV, Fadini G (2008) Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes Res Clin Pract 82(Suppl 2):S94–S101PubMed
2.
Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMed
3.
Schaper NC, Havekes B (2012) Diabetes: impaired damage control. Diabetologia 55:18–20PubMed
4.
Ii M, Takenaka H, Asai J et al (2006) Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res 98:697–704PubMed
5.
Rivard A, Silver M, Chen D et al (1999) Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 154:355–363PubMed
6.
Ebrahimian TG, Heymes C, You D et al (2006) NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am J Pathol 169:719–728PubMed
7.
Hazarika S, Dokun AO, Li Y et al (2007) Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 101:948–956PubMed
8.
Sorrentino SA, Bahlmann FH, Besler C et al (2007) Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 116:163–173PubMed
9.
Fadini GP, Agostini C, Avogaro A (2005) Endothelial progenitor cells and vascular biology in diabetes mellitus: current knowledge and future perspectives. Curr Diabetes Rev 1:41–58PubMed
10.
Fadini GP, Sartore S, Agostini C, Avogaro A (2007) Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care 30:1305–1313PubMed
11.
Fadini GP, Agostini C, Avogaro A (2010) Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 209:10–17PubMed
12.
13.
Asahara T, Murohara T, Sullivan A et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967PubMed
14.
Fadini GP, Avogaro A (2010) Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes Obes Metab 12:570–583PubMed
15.
Fadini GP, Losordo D, Dimmeler S (2012) Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 110:624–637PubMed
16.
Hagensen MK, Raarup MK, Mortensen MB et al (2012) Circulating endothelial progenitor cells do not contribute to regeneration of endothelium after murine arterial injury. Cardiovasc Res 93:223–231PubMed
17.
Hagensen MK, Shim J, Thim T, Falk E, Bentzon JF (2010) Circulating endothelial progenitor cells do not contribute to plaque endothelium in murine atherosclerosis. Circulation 121:898–905PubMed
18.
Wickersheim A, Kerber M, de Miguel LS, Plate KH, Machein MR (2009) Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. Int J Cancer 125:1771–1777PubMed
19.
Desai A, Glaser A, Liu D et al (2009) Microarray-based characterization of a colony assay used to investigate endothelial progenitor cells and relevance to endothelial function in humans. Arterioscler Thromb Vasc Biol 29:121–127PubMed
20.
Rehman J, Li J, Orschell CM, March KL (2003) Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107:1164–1169PubMed
21.
Urbich C, Aicher A, Heeschen C et al (2005) Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 39:733–742PubMed
22.
Ohtani K, Vlachojannis GJ, Koyanagi M et al (2011) Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells. Circ Res 109:1219–1229PubMed
23.
Prokopi M, Pula G, Mayr U et al (2009) Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 114:723–732PubMed
24.
Yoder MC, Mead LE, Prater D et al (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109:1801–1809PubMed
25.
He T, Smith LA, Harrington S et al (2004) Transplantation of circulating endothelial progenitor cells restores endothelial function of denuded rabbit carotid arteries. Stroke 35:2378–2384PubMed
26.
Giannotti G, Doerries C, Mocharla PS et al (2010) Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension 55:1389–1397PubMed
27.
Yoder MC (2010) Is endothelium the origin of endothelial progenitor cells? Arterioscler Thromb Vasc Biol 30:1094–1103PubMed
28.
Mund JA, Estes ML, Yoder MC, Ingram DA Jr, Case J (2012) Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells. Arterioscler Thromb Vasc Biol 32:1045–1053PubMed
29.
Tura O, Skinner EM, Barclay GR et al (2013) Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow. Stem Cells 31:338–348PubMed
30.
Thebaud NB, Bareille R, Remy M et al (2010) Human progenitor-derived endothelial cells vs. venous endothelial cells for vascular tissue engineering: an in vitro study. J Tissue Eng Regen Med 4:473–484PubMed
31.
Fadini GP, Agostini C, Avogaro A (2007) Endothelial progenitor cells in coronary artery disease. J Am Coll Cardiol 49:1585, author reply 1585-1586PubMed
32.
Zeisberger SM, Zoller S, Riegel M et al (2010) Optimization of the culturing conditions of human umbilical cord blood-derived endothelial colony-forming cells under xeno-free conditions applying a transcriptomic approach. Genes Cells 15:671–687PubMed
33.
Masuda H, Iwasaki H, Kawamoto A et al (2012) Development of serum-free quality and quantity control culture of colony-forming endothelial progenitor cell for vasculogenesis. Stem Cells Transl Med 1:160–171PubMed
34.
Kissa K, Herbomel P (2010) Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature 464:112–115PubMed
35.
Albiero M, Menegazzo L, Fadini GP (2010) Circulating smooth muscle progenitors and atherosclerosis. Trends Cardiovasc Med 20:133–140PubMed
36.
Hagensen MK, Shim J, Falk E, Bentzon JF (2011) Flanking recipient vasculature, not circulating progenitor cells, contributes to endothelium and smooth muscle in murine allograft vasculopathy. Arterioscler Thromb Vasc Biol 31:808–813PubMed
37.
Delewi R, Andriessen A, Tijssen JG et al (2013) Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a meta-analysis of randomised controlled clinical trials. Heart 99:225–232PubMed
38.
Jeevanantham V, Butler M, Saad A et al (2012) Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 126:551–568PubMed
39.
Fisher SA, Doree C, Brunskill SJ, Mathur A, Martin-Rendon E (2013) Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PLoS One 8:e64669PubMed
40.
Kandala J, Upadhyay GA, Pokushalov E et al (2013) Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol 112:217–225PubMed
41.
Fadini GP (2008) An underlying principle for the study of circulating progenitor cells in diabetes and its complications. Diabetologia 51:1091–1094PubMed
42.
Fadini GP, Pucci L, Vanacore R et al (2007) Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia 50:2156–2163PubMed
43.
Fadini GP, Miorin M, Facco M et al (2005) Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 45:1449–1457PubMed
44.
Fadini GP, Boscaro E, de Kreutzenberg S et al (2010) Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 33:1097–1102PubMed
45.
Fadini GP, Sartore S, Albiero M et al (2006) Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 26:2140–2146PubMed
46.
Fadini GP, Maruyama S, Ozaki T et al (2010) Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One 5:e11488PubMed
47.
Fadini GP, de Kreutzenberg S, Agostini C et al (2009) Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis 207:213–219PubMed
48.
Tepper OM, Galiano RD, Capla JM et al (2002) Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106:2781–2786PubMed
49.
Loomans CJ, de Koning EJ, Staal FJ et al (2004) Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53:195–199PubMed
50.
Hortenhuber T, Rami-Mehar B, Satler M et al (2013) Endothelial progenitor cells are related to glycemic control in children with type 1 diabetes over time. Diabetes Care 36:1647–1653PubMed
51.
Dessapt C, Karalliedde J, Hernandez-Fuentes M et al (2010) Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care 33:875–877PubMed
52.
Brunner S, Schernthaner GH, Satler M et al (2009) Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data. Invest Ophthalmol Vis Sci 50:392–398PubMed
53.
Palombo C, Kozakova M, Morizzo C et al (2011) Circulating endothelial progenitor cells and large artery structure and function in young subjects with uncomplicated type 1 diabetes. Cardiovasc Diabetol 10:88PubMed
54.
Sibal L, Aldibbiat A, Agarwal SC et al (2009) Circulating endothelial progenitor cells, endothelial function, carotid intima–media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia 52:1464–1473PubMed
55.
Egan CG, Lavery R, Caporali F et al (2008) Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 51:1296–1305PubMed
56.
Fadini GP, Agostini C, Sartore S, Avogaro A (2007) Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 194:46–54PubMed
57.
Choi JH, Kim KL, Huh W et al (2004) Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24:1246–1252PubMed
58.
Reinhard H, Jacobsen PK, Lajer M et al (2011) Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy. Nephron Clin Pract 118:c309–c314PubMed
59.
Makino H, Okada S, Nagumo A et al (2009) Decreased circulating CD34+ cells are associated with progression of diabetic nephropathy. Diabet Med 26:171–173PubMed
60.
Fadini GP, Sartore S, Baesso I et al (2006) Endothelial progenitor cells and the diabetic paradox. Diabetes Care 29:714–716PubMed
61.
Tan K, Lessieur E, Cutler A et al (2010) Impaired function of circulating CD34+ CD45– cells in patients with proliferative diabetic retinopathy. Exp Eye Res 91:229–237PubMed
62.
Asnaghi V, Lattanzio R, Mazzolari G et al (2006) Increased clonogenic potential of circulating endothelial progenitor cells in patients with type 1 diabetes and proliferative retinopathy. Diabetologia 49:1109–1111PubMed
63.
Brunner S, Hoellerl F, Schmid-Kubista KE et al (2011) Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease. Invest Ophthalmol Vis Sci 52:4655–4662PubMed
64.
Liu X, Li Y, Liu Y et al (2010) Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy. Am J Pathol 176:504–515PubMed
65.
Butler JM, Guthrie SM, Koc M et al (2005) SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest 115:86–93PubMed
66.
Jeong JO, Kim MO, Kim H et al (2009) Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy. Circulation 119:699–708PubMed
67.
Naruse K, Hamada Y, Nakashima E et al (2005) Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes 54:1823–1828PubMed
68.
Rohde E, Malischnik C, Thaler D et al (2006) Blood monocytes mimic endothelial progenitor cells. Stem Cells 24:357–367PubMed
69.
Asakage M, Tsuno NH, Kitayama J et al (2006) Early-outgrowth of endothelial progenitor cells can function as antigen-presenting cells. Cancer Immunol Immunother 55:708–716PubMed
70.
Urbich C, Heeschen C, Aicher A et al (2003) Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108:2511–2516PubMed
71.
Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795PubMed
72.
Mantovani A, Locati M (2013) Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol 33:1478–1483PubMed
73.
Tan K, Lessieur E, Cutler A (2013) Macrophages and chemokines as mediators of angiogenesis. Front Physiol 4:159
74.
75.
Venneri MA, de Palma M, Ponzoni M et al (2007) Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109:5276–5285PubMed
76.
He H, Xu J, Warren CM et al (2012) Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. Blood 120:3152–3162PubMed
77.
Loomans CJ, van Haperen R, Duijs JM et al (2009) Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. Mol Med 15:152–159PubMed
78.
Fadini GP, Albiero M, Boscaro E et al (2010) Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biol Int 34:709–715PubMed
79.
Bories G, Caiazzo R, Derudas B et al (2012) Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects. Diab Vasc Dis Res 9:189–195PubMed
80.
Satoh N, Shimatsu A, Himeno A et al (2010) Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care 33:e7PubMed
81.
Fadini GP, de Kreutzenberg SV, Boscaro E et al (2013) An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Diabetologia 56:1856–1866PubMed
82.
83.
Fadini GP, Albiero M, Menegazzo L et al (2012) Procalcific phenotypic drift of circulating progenitor cells in type 2 diabetes with coronary artery disease. Exp Diabetes Res 2012:921685PubMed
84.
Cui Y, Madeddu P (2011) The role of chemokines, cytokines and adhesion molecules in stem cell trafficking and homing. Curr Pharm Des 17:3271–3279PubMed
85.
Hristov M, Weber C (2009) Progenitor cell trafficking in the vascular wall. J Thromb Haemost 7(1):31–34PubMed
86.
Gossl M, Modder UI, Gulati R et al (2010) Coronary endothelial dysfunction in humans is associated with coronary retention of osteogenic endothelial progenitor cells. Eur Heart J 31:2909–2914PubMed
87.
Flammer AJ, Gossl M, Li J et al (2012) Patients with an HbA1c in the prediabetic and diabetic range have higher numbers of circulating cells with osteogenic and endothelial progenitor cell markers. J Clin Endocrinol Metab 97:4761–4768PubMed
88.
Gossl M, Khosla S, Zhang X et al (2012) Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol 60:1945–1953PubMed
89.
Gossl M, Modder UI, Atkinson EJ, Lerman A, Khosla S (2008) Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol 52:1314–1325PubMed
90.
Flammer AJ, Gossl M, Widmer RJ et al (2012) Osteocalcin positive CD133+/CD34–/KDR + progenitor cells as an independent marker for unstable atherosclerosis. Eur Heart J 33:2963–2969PubMed
91.
Fadini GP, Rattazzi M, Matsumoto T, Asahara T, Khosla S (2012) Emerging role of circulating calcifying cells in the bone-vascular axis. Circulation 125:2772–2781PubMed
92.
Fadini GP, Albiero M, Menegazzo L et al (2011) Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. Circ Res 108:1112–1121PubMed
93.
Albiero M, Rattazzi M, Menegazzo L et al (2013) Myeloid calcifying cells promote atherosclerotic calcification via paracrine activity and allograft inflammatory factor-1 overexpression. Basic Res Cardiol 108:368PubMed
94.
Hellings WE, Peeters W, Moll FL et al (2010) Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation 121:1941–1950PubMed
95.
Ehara S, Kobayashi Y, Yoshiyama M et al (2004) Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 110:3424–3429PubMed
96.
Menegazzo L, Albiero M, Millioni R et al (2013) Circulating myeloid calcifying cells have anti-angiogenic activity via thrombospondin-1 overexpression. FASEB J. doi:10.​1096/​fj.​12-223719 PubMed
97.
Kato K, Yonetsu T, Kim SJ et al (2012) Comparison of nonculprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study. JACC Cardiovasc Interv 5:1150–1158PubMed
98.
Abaci A, Oguzhan A, Kahraman S et al (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99:2239–2242PubMed
99.
Fadini GP (2013) A diseased bone marrow fuels atherosclerosis in diabetes. Atherosclerosis 226:337–338PubMed
100.
van Ark J, Moser J, Lexis CP et al (2012) Type 2 diabetes mellitus is associated with an imbalance in circulating endothelial and smooth muscle progenitor cell numbers. Diabetologia 55:2501–2512PubMed
101.
Fledderus JO, van Oostrom O, de Kleijn DP et al (2013) Increased amount of bone marrow-derived smooth muscle-like cells and accelerated atherosclerosis in diabetic apoE-deficient mice. Atherosclerosis 226:341–347PubMed
102.
Yu H, Stoneman V, Clarke M et al (2011) Bone marrow-derived smooth muscle-like cells are infrequent in advanced primary atherosclerotic plaques but promote atherosclerosis. Arterioscler Thromb Vasc Biol 31:1291–1299PubMed
103.
Bentzon JF, Sondergaard CS, Kassem M, Falk E (2007) Smooth muscle cells healing atherosclerotic plaque disruptions are of local, not blood, origin in apolipoprotein E knockout mice. Circulation 116:2053–2061PubMed
104.
Bentzon JF, Weile C, Sondergaard CS et al (2006) Smooth muscle cells in atherosclerosis originate from the local vessel wall and not circulating progenitor cells in ApoE knockout mice. Arterioscler Thromb Vasc Biol 26:2696–2702PubMed
105.
Fadini GP, Tjwa M (2010) A role for TGF-beta in transforming endothelial progenitor cells into neointimal smooth muscle cells. Atherosclerosis 211:32–35PubMed
106.
Imamura H, Ohta T, Tsunetoshi K et al (2010) Transdifferentiation of bone marrow-derived endothelial progenitor cells into the smooth muscle cell lineage mediated by tansforming growth factor-beta1. Atherosclerosis 211:114–121PubMed
107.
Westerweel PE, van Velthoven CT, Nguyen TQ et al (2010) Modulation of TGF-beta/BMP-6 expression and increased levels of circulating smooth muscle progenitor cells in a type I diabetes mouse model. Cardiovasc Diabetol 9:55PubMed
108.
Nguyen TQ, Chon H, van Nieuwenhoven FA et al (2006) Myofibroblast progenitor cells are increased in number in patients with type 1 diabetes and express less bone morphogenetic protein 6: a novel clue to adverse tissue remodelling? Diabetologia 49:1039–1048PubMed
109.
Zheng F, Cornacchia F, Schulman I et al (2004) Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors. Diabetes 53:2420–2427PubMed
110.
Menegazzo L, Albiero M, Avogaro A, Fadini GP (2012) Endothelial progenitor cells in diabetes mellitus. Biofactors 38:194–202PubMed
111.
Fadini GP (2011) Is bone marrow another target of diabetic complications? Eur J Clin Invest 41:457–463PubMed
112.
Fadini GP, Sartore S, Schiavon M et al (2006) Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 49:3075–3084PubMed
113.
Ferraro F, Lymperi S, Mendez-Ferrer S et al (2011) Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 3:104ra101PubMed
114.
Fadini GP, Avogaro A (2013) Diabetes impairs mobilization of stem cells for the treatment of cardiovascular disease: a meta-regression analysis. Int J Cardiol 168:892–897PubMed
115.
Fadini GP, Albiero M, Vigili de Kreutzenberg S et al (2013) Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 36:943–949PubMed
116.
Oikawa A, Siragusa M, Quaini F et al (2010) Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 30:498–508PubMed
117.
Spinetti G, Cordella D, Fortunato O et al (2013) Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res 112:510–522PubMed
118.
Mangialardi G, Katare R, Oikawa A et al (2013) Diabetes causes bone marrow endothelial barrier dysfunction by activation of the RhoA-Rho-associated kinase signaling pathway. Arterioscler Thromb Vasc Biol 33:555–564PubMed
119.
Fadini GP, Avogaro A (2013) Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis 229:23–29PubMed
120.
Esposito K, Maiorino MI, Di Palo C et al (2011) Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes–a randomized controlled trial. Diabetes Obes Metab 13:439–445PubMed
121.
Zhao CT, Wang M, Siu CW et al (2012) Myocardial dysfunction in patients with type 2 diabetes mellitus: role of endothelial progenitor cells and oxidative stress. Cardiovasc Diabetol 11:147PubMed
122.
Hazra S, Jarajapu YP, Stepps V et al (2013) Long-term type 1 diabetes influences haematopoietic stem cells by reducing vascular repair potential and increasing inflammatory monocyte generation in a murine model. Diabetologia 56:644–653PubMed
123.
Orlandi A, Chavakis E, Seeger F et al (2010) Long-term diabetes impairs repopulation of hematopoietic progenitor cells and dysregulates the cytokine expression in the bone marrow microenvironment in mice. Basic Res Cardiol 105:703–712PubMed
124.
Westerweel PE, Teraa M, Rafii S et al (2013) Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus. PLoS One 8:e60357PubMed
125.
Fadini GP, Albiero M, Seeger F et al (2013) Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic Res Cardiol 108:313PubMed
126.
Busik JV, Tikhonenko M, Bhatwadekar A et al (2009) Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med 206:2897–2906PubMed
127.
Ling L, Shen Y, Wang K et al (2012) Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization. PLoS One 7:e50739PubMed
Metadata
Title
A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications
Author
G. P. Fadini
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-3087-6

Other articles of this Issue 1/2014

Diabetologia 1/2014 Go to the issue

Article

Differential regulation of mouse pancreatic islet insulin secretion and Smad proteins by activin ligands

Article

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study

Letter

Risk stratification for diabetic eye screening. Reply to Stratton I. M. and Aldington S. J. [letter]

Article

NRF2 plays a protective role in diabetic retinopathy in mice

Erratum

Erratum to: Differences in metabolic and mitogenic signalling of insulin glargine and AspB10 human insulin in rats

Letter

Nitric oxide vs insulin secretion, action and clearance
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits